318 related articles for article (PubMed ID: 32019783)
1. A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis.
Refardt J; Imber C; Sailer CO; Jeanloz N; Potasso L; Kutz A; Widmer A; Urwyler SA; Ebrahimi F; Vogt DR; Winzeler B; Christ-Crain M
J Am Soc Nephrol; 2020 Mar; 31(3):615-624. PubMed ID: 32019783
[TBL] [Abstract][Full Text] [Related]
2. Treatment Effect of the SGLT2 Inhibitor Empagliflozin on Chronic Syndrome of Inappropriate Antidiuresis: Results of a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial.
Refardt J; Imber C; Nobbenhuis R; Sailer CO; Haslbauer A; Monnerat S; Bathelt C; Vogt DR; Berres M; Winzeler B; Bridenbaugh SA; Christ-Crain M
J Am Soc Nephrol; 2023 Feb; 34(2):322-332. PubMed ID: 36396331
[TBL] [Abstract][Full Text] [Related]
3. Can treatment response to SGLT2-inhibitors in syndrome of inappropriate antidiuresis be predicted by copeptin, natriuretic peptides and inflammatory markers?
Nobbenhuis R; Refardt J; Vogt D; Sailer CO; Winzeler B; Christ-Crain M
Biomarkers; 2021 Nov; 26(7):647-655. PubMed ID: 34412521
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and multiple-dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus.
Zhao X; Cui Y; Zhao S; Lang B; Broedl UC; Salsali A; Pinnetti S; Macha S
Clin Ther; 2015 Jul; 37(7):1493-502. PubMed ID: 26101175
[TBL] [Abstract][Full Text] [Related]
5. Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial.
Jensen J; Omar M; Kistorp C; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Faber J; Malik ME; Fosbøl EL; Bruun NE; Forman JL; Jensen LT; Møller JE; Schou M
Lancet Diabetes Endocrinol; 2021 Feb; 9(2):106-116. PubMed ID: 33357505
[TBL] [Abstract][Full Text] [Related]
6. Effect of hyponatremia normalization on osteoblast function in patients with SIAD.
Potasso L; Refardt J; Meier C; Christ-Crain M
Eur J Endocrinol; 2021 Nov; 186(1):1-8. PubMed ID: 34678762
[TBL] [Abstract][Full Text] [Related]
7. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
Mordi NA; Mordi IR; Singh JS; McCrimmon RJ; Struthers AD; Lang CC
Circulation; 2020 Nov; 142(18):1713-1724. PubMed ID: 32865004
[TBL] [Abstract][Full Text] [Related]
8. Case report: Twice-daily tolvaptan dosing regimen in a challenging case of hyponatremia due to SIAD.
Arecco A; Demontis D; Della Sala L; Musso N; Gay S; Boschetti M; Ferone D; Gatto F
Front Endocrinol (Lausanne); 2023; 14():1309657. PubMed ID: 38288467
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of Admission Hyponatremia in Patients With Diabetes Treated With and Without an SGLT2 inhibitor.
Monnerat S; Atila C; Refardt J; Christ-Crain M
J Endocr Soc; 2023 Feb; 7(4):bvad011. PubMed ID: 36819457
[TBL] [Abstract][Full Text] [Related]
10. Urea in cancer patients with chronic SIAD-induced hyponatremia: Old drug, new evidence.
Nervo A; D'Angelo V; Rosso D; Castellana E; Cattel F; Arvat E; Grossi E
Clin Endocrinol (Oxf); 2019 Jun; 90(6):842-848. PubMed ID: 30868608
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy of empagliflozin as an add-on treatment for chronic SIAD: a case report and literature review.
Bioletto F; Varaldo E; Prencipe N; Benso A; Berton AM
Hormones (Athens); 2023 Jun; 22(2):343-347. PubMed ID: 36656532
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes.
Heise T; Jordan J; Wanner C; Heer M; Macha S; Mattheus M; Lund SS; Woerle HJ; Broedl UC
Clin Ther; 2016 Oct; 38(10):2265-2276. PubMed ID: 27692976
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes.
Heise T; Seewaldt-Becker E; Macha S; Hantel S; Pinnetti S; Seman L; Woerle HJ
Diabetes Obes Metab; 2013 Jul; 15(7):613-21. PubMed ID: 23356556
[TBL] [Abstract][Full Text] [Related]
14. An Increase in Plasma Sodium Levels Is Associated With an Increase in Osteoblast Function in Chronic SIAD.
Monnerat S; Refardt J; Potasso L; Meier C; Christ-Crain M
J Clin Endocrinol Metab; 2023 Sep; 108(10):e1027-e1033. PubMed ID: 37098131
[TBL] [Abstract][Full Text] [Related]
15. Fluid Restriction Therapy for Chronic SIAD; Results of a Prospective Randomized Controlled Trial.
Garrahy A; Galloway I; Hannon AM; Dineen R; O'Kelly P; Tormey WP; O'Reilly MW; Williams DJ; Sherlock M; Thompson CJ
J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32879954
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Furosemide, Oral Sodium Chloride, and Fluid Restriction for Treatment of Syndrome of Inappropriate Antidiuresis (SIAD): An Open-label Randomized Controlled Study (The EFFUSE-FLUID Trial).
Krisanapan P; Vongsanim S; Pin-On P; Ruengorn C; Noppakun K
Am J Kidney Dis; 2020 Aug; 76(2):203-212. PubMed ID: 32199708
[TBL] [Abstract][Full Text] [Related]
17. Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
Anker SD; Butler J; Filippatos G; Ferreira JP; Bocchi E; Böhm M; Brunner-La Rocca HP; Choi DJ; Chopra V; Chuquiure-Valenzuela E; Giannetti N; Gomez-Mesa JE; Janssens S; Januzzi JL; Gonzalez-Juanatey JR; Merkely B; Nicholls SJ; Perrone SV; Piña IL; Ponikowski P; Senni M; Sim D; Spinar J; Squire I; Taddei S; Tsutsui H; Verma S; Vinereanu D; Zhang J; Carson P; Lam CSP; Marx N; Zeller C; Sattar N; Jamal W; Schnaidt S; Schnee JM; Brueckmann M; Pocock SJ; Zannad F; Packer M;
N Engl J Med; 2021 Oct; 385(16):1451-1461. PubMed ID: 34449189
[TBL] [Abstract][Full Text] [Related]
18. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
[TBL] [Abstract][Full Text] [Related]
19. Effect of protein supplementation on plasma sodium levels in the syndrome of inappropriate antidiuresis: a monocentric, open-label, proof-of-concept study-the TREASURE study.
Monnerat S; Atila C; Baur F; Santos de Jesus J; Refardt J; Dickenmann M; Christ-Crain M
Eur J Endocrinol; 2023 Aug; 189(2):252-261. PubMed ID: 37540987
[TBL] [Abstract][Full Text] [Related]
20. Rationale and design of the effects of EMpagliflozin on left ventricular DIAstolic function in diabetes (EmDia) study.
Jünger C; Prochaska JH; Gori T; Schulz A; Binder H; Daiber A; Koeck T; Rapp S; Lackner KJ; Münzel T; Wild PS
J Cardiovasc Med (Hagerstown); 2022 Mar; 23(3):191-197. PubMed ID: 34939776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
